Qiao Liu

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 18

Top Topics

Left Ventricular

Venous Thromboembolism

Squamous Cell Carcinoma

Small Cell Lung Cancer

Top Venues

Risk management and healthcare policy

Advances in therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Shuo Tian, Haitao Zhong, Mengyue Yin, Pei Jiang, Qiao Liu
A China-Based Cost-Effectiveness Analysis of Novel Oral Anticoagulants versus Warfarin in Patients with Left Ventricular Thrombosis. Risk management and healthcare policy 17 (2024)
Shuo Tian, Haitao Zhong, Mengyue Yin, Pei Jiang, Qiao Liu
A China-Based Cost-Effectiveness Analysis of Novel Oral Anticoagulants versus Warfarin in Patients with Left Ventricular Thrombosis. Risk management and healthcare policy 17 (2024)
Lan-Fang Li, Ran Qi, Tian-Tian Wei, Lei Feng, Xin Zhang, Qiao Liu
Cost-Effectiveness of First-Line Atezolizumab versus Chemotherapy in Non-Small-Cell Lung Cancer Patients Ineligible for Platinum-Containing Regimens. Risk management and healthcare policy 17 (2024)
Lidan Yi, Xiaohui Zeng, Zhen Zhou, Qiao Liu
Comparison Between Sotorasib with Docetaxel for the Treatment of Chinese Patients with Previously Treated NSCLC with KRASG12C Mutation: A Cost-Effectiveness Analysis to Inform Drug Pricing. Advances in therapy (2024)
Shuo Tian, Haitao Zhong, Mengyue Yin, Pei Jiang, Qiao Liu
A China-Based Cost-Effectiveness Analysis of Novel Oral Anticoagulants versus Warfarin in Patients with Left Ventricular Thrombosis. Risk management and healthcare policy 17 (2024)
Lan-Fang Li, Ran Qi, Tian-Tian Wei, Lei Feng, Xin Zhang, Qiao Liu
Cost-Effectiveness of First-Line Atezolizumab versus Chemotherapy in Non-Small-Cell Lung Cancer Patients Ineligible for Platinum-Containing Regimens. Risk management and healthcare policy 17 (2024)
Lan-Fang Li, Ran Qi, Tian-Tian Wei, Lei Feng, Xin Zhang, Qiao Liu
Cost-Effectiveness of First-Line Atezolizumab versus Chemotherapy in Non-Small-Cell Lung Cancer Patients Ineligible for Platinum-Containing Regimens. Risk management and healthcare policy 17 (2024)
Lidan Yi, Xiaohui Zeng, Zhen Zhou, Qiao Liu
Comparison Between Sotorasib with Docetaxel for the Treatment of Chinese Patients with Previously Treated NSCLC with KRASG12C Mutation: A Cost-Effectiveness Analysis to Inform Drug Pricing. Advances in therapy 41 (8) (2024)
Liting Wang, Ye Peng, Shuxia Qin, Xiaomin Wan, Xiaohui Zeng, Sini Li, Qiao Liu, Chongqing Tan
First-line systemic treatment strategies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis. PloS one 18 (4) (2023)
Ziying Zhao, Tongfeng Chen, Zhen Zhou, Rui Guo, Qiao Liu
Cost-effectiveness of camrelizumab combined with chemotherapy in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma in China. BMJ open 13 (12) (2023)
Xin Zhang, Huixian Zhang, Lan-Fang Li, Lei Feng, Qiao Liu
Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer in China. Risk management and healthcare policy 16 (2023)
Dongchu Zhou, Xinrui Dong, Zhen Zhou, Qiao Liu
Drug Pricing of Domestic Anti-PD-L1 Antibody Adebrelimab: Cost-Effectiveness Analysis of the First-Line ES-SCLC Treatment in China. Risk management and healthcare policy 16 (2023)
Ziying Zhao, Tongfeng Chen, Zhen Zhou, Rui Guo, Qiao Liu
Cost-effectiveness of camrelizumab combined with chemotherapy in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma in China. BMJ open 13 (12) (2023)
Huixian Zhang, Lanfang Li, Lei Feng, Zhen Zhou, Xin Zhang, Jianbo Feng, Qiao Liu
Biomarkers-Based Cost-Effectiveness of Toripalimab Plus Chemotherapy for Patients with Treatment-Naive Advanced Non-Small Cell Lung Cancer. Advances in therapy (2023)
Rihua Cheng, Zhen Zhou, Qiao Liu
The Cost-Effectiveness of Sugemalimab Plus Chemotherapy as First-Line Treatment for Metastatic Squamous and Non-squamous NSCLC in China. Advances in therapy (2023)
Ziying Zhao, Tongfeng Chen, Zhen Zhou, Rui Guo, Qiao Liu
Cost-effectiveness of camrelizumab combined with chemotherapy in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma in China. BMJ open 13 (12) (2023)
Ziying Zhao, Tongfeng Chen, Zhen Zhou, Rui Guo, Qiao Liu
Cost-effectiveness of camrelizumab combined with chemotherapy in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma in China. BMJ open 13 (12) (2023)
Rihua Cheng, Zhen Zhou, Qiao Liu
Cost-effectiveness of first-line versus second-line use of domestic anti-PD-1 antibody sintilimab in Chinese patients with advanced or metastatic squamous non-small cell lung cancer. Cancer medicine (2022)